Related Experiment Video
Updated: Jul 17, 2026
The Caco-2 Cell Bioassay for Measurement of Food Iron Bioavailability
Published on: April 28, 2022
Should we limit the ferritin upper threshold to 500 ng/ml in CKD patients?
Ram Dukkipati1, Kamyar Kalantar-Zadeh
1Division of Nephrology and Hypertension, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.
Insights
New guidelines for anemia in chronic kidney disease (CKD) remove some upper limits for hemoglobin and iron. However, the rationale for an upper ferritin limit of 500 ng/ml lacks evidence and may be arbitrary.
Area of Science:
- Nephrology
- Hematology
- Clinical Practice Guidelines
Background:
- Anemia is a common complication in chronic kidney disease (CKD).
- Management of anemia in CKD has been guided by clinical practice guidelines, with recent updates from the National Kidney Foundation's Kidney Disease Outcome Quality Initiative (KDOQI).
- Previous guidelines established upper thresholds for hemoglobin, transferrin saturation ratio (TSAT), and ferritin.
Purpose of the Study:
- To analyze the modifications in the KDOQI clinical practice guidelines for anemia management in CKD.
- To evaluate the implications of these changes on clinical practice and patient outcomes.
- To critically assess the evidence supporting the new recommendations, particularly regarding upper ferritin levels.
Main Methods:
- Review of the updated KDOQI clinical practice guidelines for anemia in CKD.
- Analysis of the modifications concerning hemoglobin, TSAT, and ferritin thresholds.
- Examination of the scientific literature supporting the rationale for specific ferritin recommendations.
Main Results:
- The updated guidelines eliminate upper thresholds for hemoglobin (12 g/dL), TSAT (50%), and ferritin (800 ng/ml).
- New recommendations address anemia management when hemoglobin exceeds 13 g/dL or serum ferritin is above 500 ng/ml.
- The scientific evidence supporting an upper ferritin limit of 500 ng/ml in CKD patients is deemed inadequate, as elevated ferritin levels (500-1,200 ng/ml) are not associated with increased mortality risk in hemodialysis patients when confounding factors are controlled.
Conclusions:
- The elimination of upper hemoglobin and TSAT thresholds represents a significant shift in anemia management for CKD patients.
- The selected upper ferritin level of 500 ng/ml lacks robust scientific evidence and may be arbitrary.
- Decisions regarding intravenous iron administration should consider erythropoietin responsiveness, hemoglobin, TSAT, and clinical status, rather than relying on arbitrary ferritin cutoffs.
Abstract:
The new National Kidney Foundation's Kidney Disease Outcome Quality Initiative clinical practice guidelines for anemia management in chronic kidney disease include several important modifications to the previous recommendations. These changes may have major implications in clinical practice and outcome of the chronic kidney disease patient population. Among the important guideline modifications are the elimination of the upper thresholds for hemoglobin (12 g/dL), transferrin saturation ratio (TSAT, v 50%) and ferritin (800 ng/ml). There are, however, additional recommendations pertaining to anemia management when hemoglobin is above 13 g/dL or serum ferritin above 500 ng/ml. The KDOQI anemia working group explains that the upper ferritin level of 500 ng/ml is not a stopping point for IV iron administration, but adds that decisions regarding IV iron administration should weigh erythropoietin responsiveness, hemoglobin and transferrin saturation level, and the patient's clinical status.The selected upper ferritin level of 500 ng/ml lacks adequate scientific evidence in the CKD population. Approximately half of all maintenance hemodialysis patients in the United States may have a serum ferritin above 500 ng/ml. Serum ferritin in 500-1,200 ng/ml range is not associated with increased death risk in hemodialysis patients if controlled for the confounding effect of malnutrition and inflammation. Given the lack of support from the literature, any attempt to contemplate an upper limit for serum ferritin would be arbitrary, and would not serve to improve the quality of treatment in the CKD population.
Related Concept Videos
01:28Chronic Kidney Disease III: Interprofessional Care
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:24Chronic Kidney Disease II: Clinical Manifestations
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...